Company press releases

Displaying 51 - 66 of 66 results
Released Company Title Industry Topic
11 May 2022
07:00 CEST 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Hold its Annual General Meeting on June 22, 2022 20103010 Biotechnology General meeting / Board Meeting
28 Apr 2022
07:00 CEST 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Full Year 2021 Financial Results and Highlights Operational Progress 20103010 Biotechnology Commercial results, Other subject
21 Apr 2022
07:00 CEST 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report Full Year 2021 Financial Results and Operational Progress on April 28, 2022 20103010 Biotechnology Commercial results
20 Apr 2022
12:01 CEST 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Participate at Upcoming Investor Conferences 20103010 Biotechnology Meetings / events
01 Apr 2022
08:47 CEST 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Successfully Completes Private Placement Raising EUR 21 Million 20103010 Biotechnology Change in Capital
31 Mar 2022
17:45 CEST 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Launches Capital Increase by Way of Private Placement 20103010 Biotechnology Change in Capital
07 Mar 2022
07:00 CET 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conference 20103010 Biotechnology Meetings / events
28 Feb 2022
01:00 CET 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V.: Vivoryon Therapeutics and Simcere Announce CDE Approval of Chinese Clinical Trial Application for Varoglutamstat (SIM0408, PQ912) in Patients with Alzheimer's Disease 20103010 Biotechnology Other subject
04 Jan 2022
07:00 CET 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Participate in Upcoming Investor Conferences 20103010 Biotechnology Meetings / events
22 Dec 2021
07:00 CET 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Receives FDA Fast Track Designation for Varoglutamstat in Early Alzheimer's Disease 20103010 Biotechnology Other subject
04 Nov 2021
07:00 CET 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Q3 2021 Financial Results and Highlights Operational Progress 20103010 Biotechnology Other subject
01 Nov 2021
07:00 CET 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report Third Quarter 2021 Financial Results on November 4, 2021 20103010 Biotechnology Other subject
18 Oct 2021
07:00 CEST 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Provides Update on Business and Progress of Varoglutamstat Clinical Development in Alzheimer's Disease 20103010 Biotechnology Trends / Analyses
21 Sep 2021
07:00 CEST 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports H1 2021 Financial Results and Operational Progress 20103010 Biotechnology Commercial results
14 Sep 2021
07:00 CEST 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Publish its Financial Results for H1 2021 and Operational Progress 20103010 Biotechnology Other subject
09 Sep 2021
16:41 CEST 		VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V.: Vivoryon Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference 20103010 Biotechnology Meetings / events